Nirmatrelvir-ritonavir for COVID-19

CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.

Authors

Emily G McDonald¹, Todd C Lee²

Affiliations

¹ Clinical Practice Assessment Unit (McDonald, Lee), and Divisions of Internal Medicine (McDonald) and Infectious Diseases (Lee), Department of Medicine, McGill University Health Centre, Montréal, Que. emily.mcdonald@mcgill.ca.
² Clinical Practice Assessment Unit (McDonald, Lee), and Divisions of Internal Medicine (McDonald) and Infectious Diseases (Lee), Department of Medicine, McGill University Health Centre, Montréal, Que.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Administration, Oral
COVID-19 Drug Treatment*
Cytochrome P-450 CYP3A Inhibitors / therapeutic use*
Drug Combinations
Drug Interactions
Humans
Lactams / therapeutic use*
Leucine / therapeutic use*
Nitriles / therapeutic use*
Proline / therapeutic use*
Ritonavir / therapeutic use*
SARS-CoV-2
Viral Protease Inhibitors / therapeutic use*

Substances

Cytochrome P-450 CYP3A Inhibitors
Drug Combinations
Lactams
Nitriles
Viral Protease Inhibitors
nirmatrelvir
Proline
Leucine
Ritonavir